Global Cystic Fibrosis Therapeutics Market 2016-2020

Publisher Name :
Date: 05-Oct-2016
No. of pages: 80
Inquire Before Buying

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction. The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.

The analysts forecast global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2016-2020. The report has taken into consideration the revenue generated by the vendors in the PET packaging market for packaging of different goods.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


This report, Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • AbbVie

  • F. Hoffmann-La Roche

  • Gilead Sciences

  • Novartis

  • Vertex Pharmaceuticals


Other prominent vendors


  • Advanced Inhalation Therapies (AIT)

  • Alaxia SAS

  • Alcresta Therapeutics

  • AlgiPharma

  • Allergan

  • Anthera

  • AstraZeneca

  • Bayer

  • Celtaxsys

  • Chiesi Farmaceutici

  • Corbus Pharmaceuticals

  • Cyclacel Pharmaceuticals

  • Digestive Care

  • Galapagos

  • Grifols

  • Insmed Incorporated

  • Kamada

  • Nivalis Therapeutics

  • Novoteris

  • Parion Sciences

  • Pharmaxis

  • ProQR Therapeutics

  • Protalix Biotherapeutics

  • Proteostasis Therapeutics

  • PTC Therapeutics

  • Pulmatrix

  • Savara

  • SolAeroMed

  • Vectura


Market driver


  • Special regulatory designations for drugs

  • For a full, detailed list, view our report


Market challenge


  • Discontinuation of drugs from development

  • For a full, detailed list, view our report


Market trend


  • Co-pay and assistance programs by vendors

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global Cystic Fibrosis Therapeutics Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Understanding the disease
Pathophysiology
Diagnosis
Manifestations of cystic fibrosis

PART 06: Pipeline analysis

PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08: Market segmentation by drug class
CFTR modulators
Mucolytics
PERT
Anti-infectives
Bronchodilators

PART 09: Market segmentation by molecule type
Small molecules
Biologics

PART 10: Geographical segmentation
Global cystic fibrosis therapeutics market by geography
Cystic fibrosis therapeutics market in Americas
Cystic fibrosis therapeutics market in EMEA
Cystic fibrosis therapeutics market in APAC

PART 11: Key leading countries
The US
The UK
France
Canada
Italy

PART 12: Market drivers
Special regulatory designations for drugs
Increased uptake of CFTR modulators
Improvement in diagnostic technologies

PART 13: Impact of drivers

PART 14: Market challenges
Discontinuation of drugs from development
Difficulty in developing drugs due to rarity of disease

PART 15: Impact of drivers and challenges

PART 16: Market trends
Co-pay and assistance programs by vendors
Strategic collaborations
Advances in technology for drug development and delivery

PART 17: Vendor landscape
Competitive scenario
Other prominent vendors

PART 18: Key vendor analysis
Vertex Pharmaceuticals
F. Hoffmann-La Roche
AbbVie
Gilead Sciences
Novartis

PART 19: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for global cystic fibrosis therapeutics market 2015
Exhibit 03: Key customer segments of cystic fibrosis therapeutics market
Exhibit 04: Snapshot of cystic fibrosis
Exhibit 05: Defects caused by CFTR mutation
Exhibit 06: Diagnosis of cystic fibrosis
Exhibit 07: Pipeline portfolio: Global cystic fibrosis therapeutics market
Exhibit 08: Global cystic fibrosis therapeutics market: Market overview 2015
Exhibit 09: Global cystic fibrosis therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 10: Global cystic fibrosis therapeutics market 2015-2020 ($ billions)
Exhibit 11: Opportunity analysis: Global cystic fibrosis therapeutics market
Exhibit 12: Impact of factors affecting the market 2015 and 2020
Exhibit 13: Five forces analysis
Exhibit 14: Global cystic fibrosis therapeutics by drug class 2015
Exhibit 15: Global cystic fibrosis therapeutics market by molecule type 2015
Exhibit 16: Global cystic fibrosis therapeutics market by geography 2015-2020
Exhibit 17: Percentage share of global cystic fibrosis therapeutics market by geography 2015 and 2020
Exhibit 18: Global cystic fibrosis therapeutics market by geography 2015-2020 ($ billions)
Exhibit 19: Global share of cystic fibrosis therapeutics market by geography 2015
Exhibit 20: Global cystic fibrosis therapeutics market by region: Market growth lifecycle analysis 2015
Exhibit 21: Global cystic fibrosis therapeutics market: Country analysis based on revenue and growth rate
Exhibit 22: Opportunity analysis: Cystic fibrosis therapeutics market in Americas
Exhibit 23: Cystic fibrosis therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 24: Opportunity analysis: Cystic fibrosis therapeutics market in EMEA
Exhibit 25: Cystic fibrosis therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 26: Opportunity analysis: Cystic fibrosis therapeutics market in APAC
Exhibit 27: Cystic fibrosis therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 28: Key leading countries for cystic fibrosis therapeutics market
Exhibit 29: Impact of drivers and challenges on global cystic fibrosis therapeutics market
Exhibit 30: Few drugs with breakthrough therapy designation for cystic fibrosis
Exhibit 31: Drugs with orphan drug designation for cystic fibrosis
Exhibit 32: Impact of drivers
Exhibit 33: Few cystic fibrosis therapeutics discontinued from development
Exhibit 34: Impact of drivers and challenges
Exhibit 35: Global cystic fibrosis therapeutics market: Impact assessment of key trends
Exhibit 36: Few cystic fibrosis therapeutics with patient assistance programs
Exhibit 37: Key vendors ranking 2015
Exhibit 38: Geographical presence of key vendors 2015
Exhibit 39: Competitive scenario of market vendors 2015-2020
Exhibit 40: Vertex Pharmaceuticals: Profile
Exhibit 41: Vertex Pharmaceuticals: Strength analysis
Exhibit 42: Vertex Pharmaceuticals: Growth strategy matrix
Exhibit 43: Vertex Pharmaceuticals: Opportunity assessment
Exhibit 44: Vertex Pharmaceuticals: Revenue of ORKAMBI and Kalydeco 2015 ($ millions)
Exhibit 45: F. Hoffmann-La Roche: Profile
Exhibit 46: F. Hoffmann-La Roche: Strength analysis
Exhibit 47: F. Hoffmann-La Roche: Growth strategy matrix
Exhibit 48: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 49: F. Hoffmann-La Roche: YoY growth and revenue generated from sales of Pulmozyme 2013-2015 ($ millions)
Exhibit 50: AbbVie: Profile
Exhibit 51: AbbVie: Strength analysis
Exhibit 52: AbbVie: Growth strategy matrix
Exhibit 53: AbbVie: Opportunity assessment
Exhibit 54: AbbVie: YoY growth and revenue of Creon 2013-2015 ($ millions)
Exhibit 55: Gilead Sciences: Profile
Exhibit 56: Gilead Sciences: Strength analysis
Exhibit 57: Gilead Sciences: Growth strategy matrix
Exhibit 58: Gilead Sciences: Opportunity assessment
Exhibit 59: Novartis: Profile
Exhibit 60: Novartis: Strength analysis
Exhibit 61: Novartis: Growth strategy matrix
Exhibit 62: Novartis: Opportunity assessment

  • Global Brachytherapy Afterloaders, Brachytherapy Seeds Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 06-Dec-2016        Price: US 3480 Onwards        Pages: 118
    "Brachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, and skin cancer and can also be used to treat tumors in many other body sites. Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radi......
  • Hypothyroidism - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 29
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Pipeline Review, H2 2016, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape.Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk facto......
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 63
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Pipeline Review, H2 2016, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-......
  • Behcet Disease - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 80
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H2 2016, provides an overview of the Behcet Disease (Immunology) pipeline landscape.Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat,......
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 63
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2016, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hor......
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 53
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2016, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape.Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on ......
  • United States, EU, Japan, China, India and Southeast Asia Cushings Syndrome Therapeutics Market Size, Status and Forecast 2021
    Published: 29-Nov-2016        Price: US 3300 Onwards        Pages: 91
    Notes: Production, means the output of Cushings Syndrome Therapeutics Revenue, means the sales value of Cushings Syndrome Therapeutics This report studies the global Cushings Syndrome Therapeutics market, analyzes and researches the Cushings Syndrome Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Corcept Therapeutics - HRA Pharma......
  • Global Breast Implants and Sizer Market Research Report 2016
    Published: 28-Nov-2016        Price: US 2900 Onwards        Pages: 101
    Notes: Production, means the output of Breast Implants and Sizer Revenue, means the sales value of Breast Implants and Sizer This report studies Breast Implants and Sizer in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Allergan - Natrelle - CEREPLAS - EuroSilicone -......
  • Europe Ozone Treatment Market Report 2016
    Published: 28-Nov-2016        Price: US 3900 Onwards        Pages: 112
    Notes: Sales, means the sales volume of Ozone Treatment Revenue, means the sales value of Ozone Treatment This report studies sales (consumption) of Ozone Treatment in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Kastner-Praxisbedarf GmbH - Herrmann Apparatebau GmbH - Humares ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs